 |
Contact Us Sitemap |
 |
|
 |
|
|
Latest Press Releases 2004 Press Releases 2003 Press Releases 2002 Press Releases 2001 Press Releases 2004 Annual Report Fact Sheet Contact |
 |
November 2002
November-18-2002
SciClone Pharmaceuticals to Present at RedChip Investor Conference in Phoenix
November-11-2002
ZADAXIN Significantly Increases Survival in Melanoma Animal Study - Study Presented at American Society of Clinical Oncologists (ASCO) Meeting
November-4-2002
ZADAXIN Adds Benefit to Pegylated Interferon for HCV Non-Responders - Hepatitis C Patients Who Failed Prior Therapy Responding to ZADAXIN
November-4-2002
SciClone Pharmaceuticals Reports Third Quarter 2002 Results - New Data Support Clinical Trials ZADAXIN® Sales up 20%
October 2002
October-31-2002
ZADAXIN Shows Direct Antiviral Effects on Cells Infected with Hepatitis B and HIV
October-23-2002
SciClone Pharmaceuticals to Release Third Quarter 2002 Results on November 4, 2002 - Conference Call and Webcast Scheduled
September 2002
September-28-2002
SciClone's Innovative SCV-07 Immune System Therapy Yields Positive Clinical Results in Tuberculosis - Data from Phase 2 Clinical Trials Presented at ICAAC
September-12-2002
ZADAXIN Improves Immune System's Detection of Colorectal Cancer Cells - ZADAXIN Enhances Potential for Both Therapy and Diagnosis
September-09-2002
Sciclone’s Zadaxin In Phase 2 Cancer Clinical Trial In Europe - Major Phase 2-3 Cancer Program Targets Malignant Melanoma
September-04-2002
Sciclone to Present at Bear Stearns and Redchip New York Conferences
August 2002
August-06-2002
SciClone Pharmaceuticals Reports Second Quarter 2002 Results 25% Increase in ZADAXIN® Revenues
July 2002
July-26-2002
SciClone Pharmaceuticals To Release Second Quarter 2002 Results On August 6, 2002
July-16-2002
ZADAXIN Produces Sustained Responses In Most Difficult To Treat Hepatitis B Patients
July-09-2002
ZADAXIN Increases Breast Cancer Survival Rate In NIH Animal Model
June 2002
June-07-2002
SciClone Pharmaceuticals Announces Direct Offering Of Common Stock
June-06-2002
Sciclone Pharmaceuticals Presents At UBS Warburg’s Global Specialty Pharmaceuticals Conference
May 2002
May-30-2002
SciClone Pharmaceuticals Announces Result Of 2002 Proxy Vote
May-22-2002
ZADAXIN® Selectively Stimulates Immune Systems-Related Genes Important In The Fight Against Hepatitis C Study Presented at the AASLD's Digestive Disease Week
May-15-2002
SciClone Pharmaceuticals To Webcast Presentation And Following Q&A After Annual Meeting On May 30, 2002
May-08-2002
SciClone Pharmaceuticals Reports First Quarter 2002 Results 27% Increase in ZADAXIN Revenues
April 2002
April-24-2002
SciClone Pharmaceuticals To Release First Quarter 2002 Results On May 8, 2002 Conference Call and Webcast Scheduled
April-16-2002
SciClone Sponsors First ZADAXIN® Symposium At International Conference For The Study Of The Liver Panel of Experts Discuss ZADAXIN as a Treatment for Hepatitis B
April-15-2002
SciClone Begins ZADAXIN® U.S. Phase 3 Hepatitis C Clinical Trials First Patients Enrolled and Receiving Treatment
April-09-2002
ZADAXIN® Offers New Cancer Treatment Benefits
March 2002
March-19-2002
Study Shows New Data Supporting ZADAXIN’s Ability to Increase Th1 Subset Of T-Helper Cells
March-13-2002
ZADAXIN® In Combination Therapy Has Significantly Superior Sustained Response Rates Compared To Interferon Monotherapy For Hepatitis B
March-05-2002
SciClone Pharmaceuticals Announces Positive Preliminary Data From Phase 3 Hepatitis B Trial In Japan
February 2002
February-07-2002
SciClone Pharmaceuticals Reports Fourth Quarter And Year End 2001 Results
Site design by Formative